BMC health services research · 2025
Cost-benefit analysis of universal screening for HCV infection in China: a Markov modelling study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Dachuang, Xu Liangxiu, Zhong Yimei, Xu Zhehong, Wang Jun, Wang Yuntian, Gao Yiyang, Xie Jing, Xia Yuting, Tang Wenxi
Аннотация
BACKGROUND: Hepatitis C virus (HCV) infection remains a major public health concern in China, contributing substantially to global HCV-related morbidity and mortality. In line with the World Health Organization (WHO) targets for HCV elimination by 2030, this study aimed to evaluate the long-term health and economic outcomes of universal HCV screening strategies in China.
METHODS: A decision-analytic Markov model was developed to simulate HCV disease progression and healthcare costs over a 30-year time horizon (2026-2055). A total of 81 scenarios were assessed, including 80 universal screening strategies and a no-screening comparator. Strategies varied by age group (3-10, 20-60, 60-80, or 3-80 years), screening duration (10 or 30 years), and frequency (once in 2026, or repeated every 10, 5, 3, 2 years, or annually). Model inputs were derived from published literature and national data. Cost-effectiveness was evaluated using a willingness-to-pay (WTP) threshold based on China's 2023 per capita gross domestic product, with future costs and health outcomes discounted at 5% annually. Deterministic and probabilistic sensitivity analyses were conducted.
RESULTS: Universal HCV screening was both effective and cost-effective in the majority of scenarios, with 74 out of 80 strategies demonstrating favorable cost-effectiveness ratios. Eighteen strategies met the WHO target for HCV-related mortality reduction before 2040. The most cost-effective approach-screening individuals aged 3-80 years every 5 years for 10 years-yielded an incremental net monetary benefit of US$98.99 billion (95% CI: US$10.18-190.15 billion), while reducing healthcare expenditures by US$126.67 billion compared to no screening. The required investment for screening was US$3.24 billion. Findings were robust in sensitivity analyses.
CONCLUSIONS: Universal HCV screening every 5 years for individuals aged 3-80 years over a 10-year period is highly cost-effective in China and supports national efforts toward achieving WHO HCV elimination targets. These results provide evidence to inform policy decisions in China and other middle-income settings.
METHODS: A decision-analytic Markov model was developed to simulate HCV disease progression and healthcare costs over a 30-year time horizon (2026-2055). A total of 81 scenarios were assessed, including 80 universal screening strategies and a no-screening comparator. Strategies varied by age group (3-10, 20-60, 60-80, or 3-80 years), screening duration (10 or 30 years), and frequency (once in 2026, or repeated every 10, 5, 3, 2 years, or annually). Model inputs were derived from published literature and national data. Cost-effectiveness was evaluated using a willingness-to-pay (WTP) threshold based on China's 2023 per capita gross domestic product, with future costs and health outcomes discounted at 5% annually. Deterministic and probabilistic sensitivity analyses were conducted.
RESULTS: Universal HCV screening was both effective and cost-effective in the majority of scenarios, with 74 out of 80 strategies demonstrating favorable cost-effectiveness ratios. Eighteen strategies met the WHO target for HCV-related mortality reduction before 2040. The most cost-effective approach-screening individuals aged 3-80 years every 5 years for 10 years-yielded an incremental net monetary benefit of US$98.99 billion (95% CI: US$10.18-190.15 billion), while reducing healthcare expenditures by US$126.67 billion compared to no screening. The required investment for screening was US$3.24 billion. Findings were robust in sensitivity analyses.
CONCLUSIONS: Universal HCV screening every 5 years for individuals aged 3-80 years over a 10-year period is highly cost-effective in China and supports national efforts toward achieving WHO HCV elimination targets. These results provide evidence to inform policy decisions in China and other middle-income settings.